





THE PREPRINT SERVER FOR HEALTH SCIENCES

HOME I ABOUT	SUBMIT	<b>NEWS &amp; NOTES</b>	ALERTS / RSS

Search	Q
	Advanced Search

Comment on this paper

# Safety of Focused Ultrasound Neuromodulation in Humans with Temporal Lobe Epilepsy

Dohn Stern, Alexander Korb, Dorman M Spivak, Sergio Becerra, Doavid Kronemyer, Negar Khanlou, Samuel D Reyes, Martin M Monti, Docaroline Schnakers, Patricia Walshaw, Dordan, Taylor P Kuhn, Mark S Cohen, William Yong, Doltzhak Fried, Sheldon Jordan, Jerome Engel Jr., Mark E Schafer, Alexander Bystritsky

doi: https://doi.org/10.1101/2020.04.10.20060855

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

**Abstract** 

Info/History

Metrics

Preview PDF

#### **Abstract**

Objective: Low-Intensity Focused Ultrasound Pulsations (LIFUP) is a promising new potential neuromodulation tool. However, the safety of LIFUP neuromodulation has not yet been adequately assessed. Patients with refractory temporal lobe epilepsy electing to undergo an anterior temporal lobe resection present a unique opportunity to evaluate the safety and efficacy of LIFUP neuromodulation. Because the brain tissue in these patients will be removed, histological changes in tissue after LIFUP can be examined. Evidence of effective neuromodulation was assessed using functional MRI and EEG, while further potential safety concerns were assessed using neuropsychological testing. Methods: EEG, functional MRI, and neuropsychology were assessed in six patients before and 2 after focused ultrasound sonication of the temporal lobe at intensities up to 5760 mW/cm. Using the BrainSonix Pulsar 1002, LIFUP was delivered under MR guidance, using the Siemens Magnetom 3T Prisma scanner. Neuropsychological changes were assessed using various batteries. EEG was recorded using the

Electrical Geodesics EGI 256 channel system. Histological changes were assessed using hematoxylin

and eosin staining, among others. Results: LIFUP was not able to modulate the BOLD signal on fMRI in a reliable and consistent manner. The EEG data that was available did not demonstrate a change in activity after LIFUP in all but one subject. Likewise, the neuropsychology testing did not show any statistically significant changes in any test, except for a slight decrease in performance on the one test after LIFUP. Lastly, the histology did not reveal any detectable damage to the tissue, except for one subject for whom the histology findings were inconclusive. Significance: The safety in the histology was the primary endpoint, and as such, longer exposure at the highest intensity levels will be administered moving forward.

## **Competing Interest Statement**

Dr. Korb is Vice-President of BrainSonix Corp and owns shares in the company. Dr. Bystritsky is the Founder and CEO of BrainSonix Corp. Other authors report no conflicts of interest.

#### **Clinical Trial**

NCT02151175

## **Funding Statement**

This study received funding from the BrainSonix Corporation and the Friedman Foundation.

### **Author Declarations**

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

# Copyright

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Tweets referencing this article:




15 Apr 2020

## medRxiv Comment Policy

Comments are moderated for offensive or irrelevant content (can take ~24 hours). Duplicated submission is unnecessary.

Please read our Comment Policy before commenting.



# COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

## Neurology

# **Subject Areas**

### **All Articles**

A	d	d	i	C	ri	0	n	M	Р	d	ic	iı	ne	Δ

Allergy and Immunology

Anesthesia

Cardiovascular Medicine

Dentistry and Oral Medicine

Dermatology

**Emergency Medicine** 

Endocrinology (including Diabetes Mellitus and Metabolic Disease)

**Epidemiology** 

Forensic Medicine

Gastroenterology

Genetic and Genomic Medicine

Geriatric Medicine

**Health Economics** 

Health Informatics

Health Policy

Health Systems and Quality Improvement

Hematology

HIV/AIDS

Infectious Diseases (except HIV/AIDS)

Intensive Care and Critical Care Medicine

Medical Education

Medical Ethics

Nephrology

Neurology

Nursing

Nutrition

Obstetrics and Gynecology

Occupational and Environmental Health

Oncology
Ophthalmology
Orthopedics
Otolaryngology
Pain Medicine
Palliative Medicine
Pathology
Pediatrics
Pharmacology and Therapeutics
Primary Care Research
Psychiatry and Clinical Psychology
Public and Global Health
Radiology and Imaging
Rehabilitation Medicine and Physical Therapy
Respiratory Medicine
Rheumatology
Sexual and Reproductive Health
Sports Medicine
Surgery
Toxicology
Transplantation
Urology

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

Continue

Find out more